Correlation Engine 2.0
Clear Search sequence regions


Diaryl ether family as one of the promising second generation HIV-1 non-nucleoside reverse transcriptase inhibitors has attracted considerable attention over the past few years, among which clinical candidate MK-4965 has been advanced into phase II clinical trials. The successful development of diaryl ether family provides valuable avenues in traditional medicinal chemistry, crystallography and computer-aided drug design fields for the design of other novel anti-HIV drug candidates. In this review, the development of diaryl ether family is present including the evolutionary history, design strategies, extensive structural modifications, structure-activity relationship studies and computer-aided molecular simulation of the binding mode in detail.

Citation

Xuwang Chen, Shufang Ding, Peng Zhan, Xinyong Liu. Recent advances of diaryl ether family as HIV-1 non-nucleoside reverse transcriptase inhibitors. Current pharmaceutical design. 2013;19(15):2829-38

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 23343121

View Full Text